New vaccine offers hope in fight against disease that threatens half of world's population: 'Ensuring a sufficient vaccine supply is critical'
Dengue fever is transmitted through mosquito bites that cause flu-like symptoms such as a high fever, rash, vomiting, and joint, bone, or muscle pain, according to the Cleveland Clinic. Those symptoms can also become more severe during reinfection.
Thankfully, the QDENGA® dengue vaccine will be available in India by 2026. However, it's not the first-ever dengue fever vaccine to reach the market. The vaccine Dengvaxia® was approved in 2019 by the FDA but is no longer available in the United States, even in endemic areas like Puerto Rico. That same vaccine wasn't useful for those without a past dengue infection, either.
In contrast, Qdenga will have better availability to prevent outbreaks. "Our vaccine has been approved in 40 countries, and we anticipate the vaccine will be licensed in India in 2026," Derek Wallace, Takeda's global vaccine business unit president, told The Times of India.
"Given that dengue threatens half the world's population, ensuring a sufficient vaccine supply is critical," Wallace said. This vaccine isn't the only way to fight this disease, as a warming climate — an issue directly caused by human behavior — has already fostered an environment for the disease to thrive. According to the World Health Organization, rising atmospheric heat and humidity have increased outbreak numbers in recent years.
Mosquitos are increasingly spreading the disease as the overheating planet makes it easier for them to survive and reproduce more. Massive storms and flooding can produce lots of standing water where one mosquito can lay as many as 50 to 200 eggs at one time.
Poor sanitation, such as "garbage lasagnas," can give off heat or maintain standing water, providing breeding grounds for them to thrive. The Stanford Report discusses the link between mosquito-borne diseases like dengue and malaria and trash in Kenya. However, reducing landfill material and heat-trapping carbon exhaust is within human reach to solve through recycling, home/vehicle electrification, and solar conversion.
Working toward a cooler and cleaner planet also helps maintain safe vaccine storage. Disasters can shut down facilities that keep vaccines cool and make access hard for those in remote areas. Therefore, communities, stakeholders, and vaccine producers working together are essential to world health.
Do you worry about the quality of the air inside your home?
Yes — often
Yes — but only sometimes
Only when it's bad outside
No — I never do
Click your choice to see results and speak your mind.
Join our free newsletter for good news and useful tips, and don't miss this cool list of easy ways to help yourself while helping the planet.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Miami Herald
2 hours ago
- Miami Herald
The Versailles Hospital Center Chooses Tribun Health for Its Transition to Digital Pathology
A Major Step Toward Precision Diagnostics with the Implementation of CaloPix® PARIS, FRANCE / ACCESS Newswire / July 3, 2025 / Tribun Health, European leader in AI-enhanced digital pathology, is proud to announce that the Versailles Hospital Center, the supporting institution of GHT 78 Sud, has selected its imaging platform, CaloPix®, to support the digital transformation of its pathology department. This decision represents a strategic milestone in modernizing diagnostic services within the French public healthcare system. Through this project, the Versailles Hospital Center joins a growing network of pioneering institutions leveraging Tribun Health's technologies to optimize workflows, enhance diagnostic quality, and prepare for the integration of artificial intelligence. "We are honored by the trust that the Versailles Hospital Center has placed in us," said Jean-François POMEROL, CEO of Tribun Health. "This choice reflects a shared commitment to innovating for more effective, collaborative, and patient-centered healthcare." "The selection of CaloPix® is fully aligned with our digital transformation strategy," explained Dr. Claire GLASER, Head of the Pathology Department at the Versailles Hospital Center. "We were impressed by the solution's user-friendliness, performance, and the quality of support offered by Tribun Health's teams. This project, developed in collaboration with the GHT Yvelines Nord, marks a key step for the future of our specialty in the region, particularly regarding AI and collaborative work. It also enhances our integration into APHP's expert networks equipped with the same software." CaloPix® will be deployed throughout the pathology department to support primary diagnostics, interdisciplinary collaboration, and the future integration of AI solutions. Known for its intuitive interface, high performance, and adaptability to the evolving needs of hospital structures, the platform is open and interoperable. This project is fully aligned with the digital strategy of the Versailles Hospital Center and GHT 78 Sud, in collaboration with GHT Nord, and reflects a national plan aimed at modernizing and digitizing healthcare infrastructures. It is also part of a strong regional initiative and will serve as an interoperability foundation within the GHTs of the Yvelines region. About Tribun Health Tribun Health, recognized under the French Tech 2030 label, is a global leader in digital pathology, offering award-winning solutions that improve workflow efficiency, diagnostic accuracy, and patient outcomes. We assist hospitals and laboratories in transitioning from glass slide pathology to fully digital solutions, leveraging AI and data-driven technology to enhance precision and reduce turnaround times. Our mission is simple: to ensure every cancer patient receives a timely and informed diagnosis-because every moment counts. By advancing pathology with cutting-edge innovations, we are shaping the future of cancer care. For more information, visit Tribun Health and follow us on LinkedIn and X. Contact Information Andreia Beyer VP, Global Marketing & Managing Director, North Americaabeyer@ (416) 565-0474 SOURCE: Tribun Health press release
Business Wire
2 hours ago
- Business Wire
ImmunoPrecise Validates LENS ai Epitope Mapping Platform Across Broad Range of Unseen Therapeutic Targets Beyond Training Data
AUSTIN, Texas--(BUSINESS WIRE)--ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) ('IPA' or the 'Company'), an AI-powered biotherapeutics company, today announced a new validation study supporting the generalizability of its proprietary epitope mapping platform, LENS ai, powered by IPA's patented HYFT® technology. The newly released benchmark shows that the platform consistently delivers high predictive performance, even on complexes not used during training. LENSai accurately mapped antibody binding sites on entirely new antibody - protein complexes-none of which were used in training. Not the antibodies. Not the targets. Not the complexes. 'It's generally assumed that AI can only make accurate predictions if it has seen similar data before,' said Dr. Jennifer Bath, CEO of ImmunoPrecise. 'But this benchmark proves otherwise: LENS ai accurately mapped antibody binding sites on entirely new antibody - protein complexes-none of which were used in training. Not the antibodies. Not the targets. Not the complexes. And the predictions aligned with wet-lab results. This is a major breakthrough in generalizing AI for therapeutic discovery, made possible by our proprietary technology, which captures functional meaning instead of memorizing shapes. It shows that AI doesn't always need massive data to be powerful and accurate - it just needs the right kind.' LENS ai Epitope Mapping uses artificial intelligence to pinpoint where antibodies are most likely to attach to disease-related proteins - helping scientists design better treatments faster. Unlike traditional methods that take months and require lab work, LENS ai delivers results in hours - using just the digital sequences - cutting timelines, eliminating the need to produce expensive materials, reducing guesswork, and unlocking faster paths to new treatments. In a new benchmark study, LENS ai was tested on 30 antibody-protein pairs, 17 of which the platform had never seen before. Despite having no prior exposure to these molecules, LENS ai achieved prediction scores nearly identical to those from its original training data. This score, known as AUC (Area Under the Curve), is a widely accepted measure of accuracy in computational biology. The consistent performance on entirely new, unseen complexes confirms that LENS ai 's artificial intelligence can reliably analyze and predict antibody binding - even for molecules outside its training set. This breakthrough demonstrates LENS ai 's power to generalize across diverse biological structures, making it a valuable tool for accelerating real-world drug discovery. Why This Benchmark Matters In the new study, LENS ai delivered high accuracy results on 17 antibody-protein complexes the platform had never seen before as it did on familiar training examples - proving true generalization, not memorization. Because no new wet-lab work or x-ray structures were required, researchers gain speed, reproducibility, and major cost savings, while freeing scarce lab resources for confirmatory or downstream assays. What It Means for Partners and Investors With LENS ai already embedded in collaborations across big pharma and biotech, ImmunoPrecise is scaling access through secure APIs and custom partnerships. The platform helps researchers compress discovery timelines, reduce risk, and unlock previously unreachable targets - positioning the company and its investors at the forefront of AI-driven antibody therapeutics. For more technical detail and full benchmark results, explore two complementary case studies that illustrate the power and flexibility of LENS ai Epitope Mapping. The first highlights performance on a 'seen' target, where the system was trained on related data. The second - featured in this press release - demonstrates LENS ai 's breakthrough ability to accurately map binding sites on a completely 'unseen' target, with no prior exposure to the antibody, the antigen, or their structure. These examples underscore how LENS ai performs both in well-characterized systems and in novel, previously untrained scenarios—validating its generalizability and real-world readiness. About ImmunoPrecise Antibodies Ltd. ImmunoPrecise (NASDAQ: IPA) is a global leader in AI-powered biotherapeutic discovery and development. Its proprietary HYFT technology and LENSai™ platform enable first-principles-based drug design, delivering validated therapeutic candidates across modalities and therapeutic areas. IPA partners with 19 of the top 20 pharmaceutical companies and is advancing next-generation biologics through data-driven, human-relevant models. Forward-Looking Statements This press release contains forward-looking statements within the meaning of applicable United States and Canadian securities laws. Forward-looking statements are often identified by words such as 'expects,' 'intends,' 'plans,' 'anticipates,' 'believes,' or similar expressions, or by statements that certain actions, events, or results 'may,' 'will,' 'could,' or 'might' occur or be achieved. These statements include, but are not limited to, statements regarding the performance, scalability, and broader application of the LENSai™ and HYFT® platforms; the generalizability of the Company's AI models to novel therapeutic targets; the role of AI in accelerating antibody discovery; and the Company's future scientific, commercial, and strategic developments. Forward-looking statements are based on management's current expectations, assumptions, and projections about future events. Actual results may differ materially from those expressed or implied due to a variety of factors, many of which are beyond the Company's control. These factors include, but are not limited to, the pace of scientific and technological innovation, risks related to model validation and generalizability in real-world settings, intellectual property protection, strategic partner adoption, regulatory pathways, and market demand for AI-driven therapeutic platforms. Forward-looking statements involve known and unknown risks, uncertainties, and other factors that could cause actual results, performance, or achievements to differ materially from those expressed or implied herein. Additional information regarding risks and uncertainties is included in the Company's Annual Report on Form 20-F, as amended, for the year ended April 30, 2024 (available on the Company's SEDAR+ profile at and EDGAR profile at Should any of these risks materialize, actual results could vary significantly from those currently anticipated. Readers are cautioned not to place undue reliance on these forward-looking statements. Except as required by law, the Company undertakes no obligation to update or revise forward-looking statements to reflect subsequent events or circumstances.
Business Wire
8 hours ago
- Business Wire
Transition of Promotional Activities for Allergen Immunotherapy Drug Actair® in Japan
BAAR, Switzerland & OSAKA, Japan & TOKYO--(BUSINESS WIRE)--Stallergenes Greer, Shionogi & Co., Ltd. ('Shionogi') and CEOLIA Pharma Co. Ltd ('CEOLIA') today announced the transition of promotional activities for Actair® in Japan. Actair® is Stallergenes Greer's sublingual immunotherapy tablet for the treatment of patients suffering from house dust mite induced allergic rhinitis. After ending the license agreement established in 2010 with Shionogi, which had been responsible for developing, registering, and commercialising Actair® in Japan, Stallergenes Greer has appointed CEOLIA as its new promotional partner in the country starting July 3. To ensure the continuity of both patient care and support for healthcare professionals, Shionogi will continue during a transition period to serve as the Marketing Authorisation Holder (MAH) in Japan and remain responsible for the importation, manufacturing and distribution of Actair®. Shionogi will also provide active support to CEOLIA by transferring knowledge and offering operational assistance. Stallergenes Greer acknowledges Shionogi's contribution and sustained commitment to improving allergy care in Japan. The company welcomes CEOLIA as a trusted new partner and looks forward to working closely together to further advance access to allergen immunotherapy treatments and continue to improve the quality of life of patients with respiratory allergies. ABOUT STALLERGENES GREER Headquartered in Baar (Switzerland), Stallergenes Greer is a global healthcare company specialising in the diagnosis and treatment of allergies through the development and commercialisation of allergen immunotherapy products and services. Supported by more than 100 years of expertise and innovation, our products are available for patients in over 40 countries. For more information, visit ABOUT SHIONOGI & Co. Ltd Shionogi has identified 'Contributing to a Healthy and Prosperous Life' as one of its key material issues. The group is committed to building a society where everyone can live vibrantly and true to themselves. With a continued focus on areas of high unmet medical needs, Shionogi strives to deliver innovative treatments that improve the quality of life (QOL) for patients and their families. For more information, visit ABOUT CEOLIA CEOLIA, founded in 2010, is a pharmaceutical company dedicated to serving all healthcare needs in the otolaryngology (ENT) field. With a mission and philosophy to serve and contribute to people's health and happiness, we develop and manufacture and market ethical drugs, medical devices, and diagnostic reagents in the ENT field. For more information, visit
